Bejelentkezés Regisztrálj ingyen

RepliCel Life Sciences Beta

Mi az RepliCel Life Sciences Beta?

A Beta az RepliCel Life Sciences, Inc. - 0.97

Mi a Beta meghatározása?



A BETA azt jelzi, hogy az állomány több-kevésbé volatilis, mint a piac egésze. Az 1-nél kevesebb béta azt jelzi, hogy az állomány kevésbé ingadozó, mint a piac, míg az 1-nél nagyobb béta azt jelzi, hogy az állomány volatilisabb. A volatilitást az átlag körüli ár ingadozásaként méri.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta a Health Care szektor a TSXV-on cégekben a RepliCel Life Sciences -hoz képest

Mit csinál RepliCel Life Sciences?

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.

beta -hoz hasonló cégek RepliCel Life Sciences